Plaque Psoriasis Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Plaque Psoriasis pipeline constitutes 75+ key companies continuously working towards developing 75+ Plaque Psoriasis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Plaque Psoriasis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Plaque Psoriasis Market.

The Plaque Psoriasis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Plaque Psoriasis Pipeline Report: https://www.delveinsight.com/sample-request/plaque-psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Plaque Psoriasis treatment therapies with a considerable amount of success over the years.
• Plaque Psoriasis companies working in the treatment market are Dermavant Sciences GmbH, IQVIA Biotech, UCB Biopharma SRL, Parexel, Samsung Bioepis Co., Ltd, Durect, Astellas, Biogen, Dow Pharmaceutical Sciences, Shire, Zalicus, AbbVie, Santalis Pharmaceuticals Inc, Maruho Co Ltd, Novartis, AstraZeneca, Pfizer, and others, are developing therapies for the Plaque Psoriasis treatment
• Emerging Plaque Psoriasis therapies in the different phases of clinical trials are- AX-158, tapinarof cream, 1%, TAK-279, TQH3906 capsules, Apremilast, Cetaphil, LY3972406, GNR-068, D-2570, ZL-1102, ESK-001, Deucravacitinib, JNJ-77242113, and others are expected to have a significant impact on the Plaque Psoriasis market in the coming years.
• In June 2025, Sun Pharmaceutical Industries Limited released top-line findings from its Phase 2 clinical trial assessing the safety and efficacy of SCD-044, an innovative oral sphingosine-1-phosphate (S1P) receptor 1 agonist, in patients with moderate to severe psoriasis. The trial did not achieve its primary goal of demonstrating a 75% improvement in the Psoriasis Area and Severity Index (PASI ≥75) at Week 16. This Phase 2 randomized, double-blind, placebo-controlled study involved 263 participants diagnosed with moderate to severe plaque psoriasis.
• In May 2025, Johnson & Johnson (J&J) released updated findings from its Phase III ICONIC-TOTAL trial investigating icotrokinra, an oral peptide, for the treatment of plaque psoriasis (PsO). The randomized study included both adult and adolescent patients aged 12 years and older, with a body surface area involvement as low as 1% and moderate or greater psoriasis affecting key skin regions.
• In February 2025, Bristol Myers Squibb (BMS), a US-based pharmaceutical company, announced results from the POETYK PSO long-term extension (LTE) trial evaluating Sotyktu (deucravacitinib) for plaque psoriasis. The LTE trial included the 52-week POETYK PSO-1 and POETYK PSO-2 studies, involving 1,221 participants who received a 6mg daily dose of open-label Sotyktu.
• In February 2025, Vyne Therapeutics initiated a randomized Phase Ib clinical trial by dosing the first participant with VYN202, an oral therapy for moderate-to-severe plaque psoriasis. This double-blind, placebo-controlled study includes three dosing groups to evaluate the treatment's safety, pharmacokinetics, and tolerability. Participants will receive either 0.25mg, 0.5mg, or 1mg doses of VYN202, or a placebo, administered once daily over a 12-week period.
• In December 2024, Bristol Myers Squibb (NYSE: BMY) announced findings from the POETYK PsA-1 (IM011-054) and POETYK PsA-2 (IM011-055) Phase 3 trials assessing the efficacy and safety of Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA). Both studies achieved their primary endpoint, demonstrating a significantly higher percentage of Sotyktu-treated patients attaining an ACR20 response-indicating at least a 20% improvement in disease signs and symptoms-after 16 weeks of treatment compared to placebo.
• In October 2024, InnoCare Pharma has reported that its Phase II clinical trial of the Tyrosine Kinase 2 (TYK2) inhibitor ICP-488 for psoriasis treatment achieved the primary endpoint. The multicenter, randomized, double-blind, placebo-controlled study aimed to assess the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of ICP-488 in adult Chinese patients with moderate-to-severe plaque psoriasis.
• In August 2024, Amgen (NASDAQ:AMGN) announced today that Otezla® (apremilast) is now available in the U.S. for pediatric use. Earlier this year, the U.S. Food and Drug Administration (FDA) approved Otezla for treating moderate to severe plaque psoriasis in children and adolescents aged 6 and older, weighing at least 20 kg (44 lb), and who are suitable candidates for phototherapy or systemic therapy. Currently, there are no other FDA-approved oral treatments for moderate to severe plaque psoriasis in this age group.

Plaque Psoriasis Overview
Psoriasis vulgaris, also known as plaque psoriasis, is a persistent (chronic) autoimmune condition that accelerates cell division. It is a kind of psoriasis that results in plaques on the skin, which are thick, scaly regions. Approximately 8 million Americans suffer from the skin condition psoriasis.

Get a Free Sample PDF Report to know more about Plaque Psoriasis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/plaque-psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Plaque Psoriasis Drugs Under Different Phases of Clinical Development Include:
• AX-158: Artax Biopharma Inc
• tapinarof cream, 1%: Dermavant Sciences, Inc.
• TAK-279: Takeda
• TQH3906 capsules: Chia Tai Tianqing Pharmaceutical
• Apremilast: Amgen
• Cetaphil: Galderma R&D
• LY3972406: Eli Lilly and Company
• GNR-068: AO GENERIUM
• D-2570: InventisBio Co., Ltd
• ZL-1102: Zai Lab
• ESK-001: Alumis Inc
• Deucravacitinib: Bristol-Myers Squibb
• JNJ-77242113: Janssen Research & Development

Plaque Psoriasis Route of Administration
Plaque Psoriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Plaque Psoriasis Molecule Type
Plaque Psoriasis Products have been categorized under various Molecule types, such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Plaque Psoriasis Pipeline Therapeutics Assessment
• Plaque Psoriasis Assessment by Product Type
• Plaque Psoriasis By Stage and Product Type
• Plaque Psoriasis Assessment by Route of Administration
• Plaque Psoriasis By Stage and Route of Administration
• Plaque Psoriasis Assessment by Molecule Type
• Plaque Psoriasis by Stage and Molecule Type

DelveInsight's Plaque Psoriasis Report covers around 75+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Plaque Psoriasis product details are provided in the report. Download the Plaque Psoriasis pipeline report to learn more about the emerging Plaque Psoriasis therapies
https://www.delveinsight.com/sample-request/plaque-psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Plaque Psoriasis Therapeutics Market include:
Key companies developing therapies for Plaque Psoriasis are - Arcutis Biotherapeutics, Affibody, Akeso Biopharma, Dong-A ST Co., Ltd., DelArrivo, Inc., Bristol-Myers Squibb, Bio-Thera Solutions, Janssen Research & Development, LLC, Meiji Pharma USA Inc., Aldeyra Therapeutics, Inc., Amgen, Bioeq GmbH, Can-Fite Biopharma, Hangzhou Highlightll Pharmaceutical Co., Ltd, Nimbus Therapeutics, Sun Pharmaceutical Industries, Jiangsu Hengrui Medicine, Ono Pharmaceutical, GC Cell Corporation, Suzhou Zelgen Biopharmaceuticals, Aurigene Discovery Technologies Limited, Celltrion, Tianjin Hemay Pharmaceutical Co., Ltd, Innovent Biologics (Suzhou) Co. Ltd., Sinocelltech, Azora Therapeutics, Biocon, and others.

Plaque Psoriasis Pipeline Analysis:
The Plaque Psoriasis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Plaque Psoriasis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Plaque Psoriasis Treatment.
• Plaque Psoriasis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Plaque Psoriasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Plaque Psoriasis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Plaque Psoriasis drugs and therapies
https://www.delveinsight.com/sample-request/plaque-psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Plaque Psoriasis Pipeline Market Drivers
• Growing worldwide prevalence, ongoing research and development activities to identify novel and targeted therapies, increase in Awareness about the disease are some of the important factors that are fueling the Plaque Psoriasis Market.

Plaque Psoriasis Pipeline Market Barriers
• However, poor adherence and compliance with medications, challenging disease in terms of management and other factors are creating obstacles in the Plaque Psoriasis Market growth.

Scope of Plaque Psoriasis Pipeline Drug Insight
• Coverage: Global
• Key Plaque Psoriasis Companies: Dermavant Sciences GmbH, IQVIA Biotech, UCB Biopharma SRL, Parexel, Samsung Bioepis Co., Ltd, Durect, Astellas, Biogen, Dow Pharmaceutical Sciences, Shire, Zalicus, AbbVie, Santalis Pharmaceuticals Inc, Maruho Co Ltd, Novartis, AstraZeneca, Pfizer, and others
• Key Plaque Psoriasis Therapies: AX-158, tapinarof cream, 1%, TAK-279, TQH3906 capsules, Apremilast, Cetaphil, LY3972406, GNR-068, D-2570, ZL-1102, ESK-001, Deucravacitinib, JNJ-77242113, and others
• Plaque Psoriasis Therapeutic Assessment: Plaque Psoriasis current marketed and Plaque Psoriasis emerging therapies
• Plaque Psoriasis Market Dynamics: Plaque Psoriasis market drivers and Plaque Psoriasis market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.